Radio Cadena Agramonte emisiora de Camagüey
Havana, Jan 26. - Despite facing a very difficult year, primarily due to the impact of the U.S. government's economic blockade, in 2025 the BioCubaFarma Business Group demonstrated significant progress in research and the development of new products and health registrations.
Doctor of Sciences Santiago Dueñas Carrera, vice president of the organization, explained to Granma that 408 projects were executed, of which over a hundred were carried out in cooperation with various national entities.
He also highlighted the achievement of 20 high-impact scientific-technological results, such as the introduction of Sodium Enoxaparin into the national health system, a drug used to prevent and treat deep vein thrombosis, among other applications.
The list includes the development of an animal biomodel for studying metabolic syndrome in humans, and the attainment of two registrations: the health registration of Sincronida, for cattle reproduction, and the definitive registration of the monoclonal antibody Racotumamab, as maintenance therapy for patients with advanced non-small cell lung cancer.
Transgenic sugarcane lines resistant to smut and rust were also obtained.
According to the executive, the list also includes the introduction of a calcium carbonate nutritional supplement with raw materials of national production, and the registration and industrialization of the vitamin B complex: Polivitsin, as well as Lisinopril with Hydrochlorothiazide tablets of 20 and 25 milligrams, the formulation and introduction of the insecticide lpu 0.5, and the evaluation of the effects of long-term treatment with policosanol (ppg) plus aspirin on the functional recovery of patients with ischemic stroke and post-stroke cognitive impairment.
In clinical research, the Vice President of BioCubaFarma detailed, evidence was reported of the favorable effect of the drug Jusvinza in treating patients with Chikungunya sequelae, while the first clinical trial of the same drug began in China, for its future use in the therapeutic regimen for rheumatoid arthritis.
Other contributions were related to the implementation of preclinical zebrafish models for drug research and development, the health registration of the Sumasignal Apoe and Umtest msud diagnostic systems, evidence of the therapeutic effects of the monoclonal antibody Neuralcim in patients with amnestic Alzheimer's-type syndrome in mild-moderate stages and with ataxia, and the optimization of fermentation processes and mathematical modeling to accelerate vaccine development.
In the entity's work during 2025, the submission of six new patent applications stands out, reflecting the priority given to executing innovative projects, while 42 patents were granted abroad and seven in our country.
In the entity's work during 2025, the submission of six new patent applications stands out, reflecting the priority given to executing innovative projects, while 42 patents were granted abroad and seven in our country.
Likewise, new joint ventures were created in Vietnam, Italy, Russia, and Australia, designed to accelerate the development and introduction of novel biopharmaceutical products, while collaboration with institutions in China continued to be promoted, stated Dr. Santiago Dueñas.
He emphasized that the number of scientific articles published in international media reached 178, with 86 in high-visibility journals, while a total of 42 new health registrations were approved abroad. (Text and photo: Granma Digital)
